found that patients with Lynch syndrome-associated MMR gene variations are not only prone to uroepithelial cancer, but also have a significantly higher risk of bladder cancer; thus, screening for Lynch-associated tumors should also include a screening for bladder cancer (15). This evidence concerns the gene MRC1 and Lynch syndrome.